Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company at the forefront of developing innovative bi-functional fusion proteins. These unique proteins represent a new class of biologic medicine aimed at treating patients with cancer and autoimmune diseases. Shattuck's proprietary Agonist Redirected Checkpoint (ARC®) platform is designed to inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic, a groundbreaking approach in the biotechnology field.
The company's lead product candidate, SL-172154 (SIRPα-Fc-CD40L), is engineered to block the CD47 immune checkpoint and activate the CD40 pathway simultaneously. Currently, SL-172154 is in multiple Phase 1 clinical trials targeting various cancers, including platinum-resistant ovarian cancer and acute myeloid leukemia (AML). Another promising candidate, SL-279252 (PD1-Fc-OX40L), is being developed in collaboration with Takeda Pharmaceuticals and is also in Phase 1 trials.
Shattuck Labs recently embarked on an exciting collaboration with Ono Pharmaceutical to develop bifunctional fusion proteins for autoimmune and inflammatory diseases. This partnership includes a significant financial package with potential milestone payments and royalties, reinforcing Shattuck's strong financial condition and innovative capabilities. Additionally, the company's proprietary gamma delta T cell engager platform, GADLEN™, promises to bridge gamma delta T cells to tumor antigens, offering new hope for cancer treatment.
Recent achievements include rapid enrollment in clinical trials and the FDA's orphan drug designation for SL-172154, highlighting the urgent need for new AML treatments. Shattuck is also actively participating in several high-profile conferences, sharing their latest research and clinical progress. The company is headquartered in Austin, Texas, and Durham, North Carolina, and continues to leverage its scientific expertise to address unmet medical needs.
- Core Business: Development of bi-functional fusion proteins for cancer and autoimmune diseases.
- Recent Achievements: FDA orphan drug designation for SL-172154, collaboration with Ono Pharmaceutical.
- Current Projects: Phase 1 trials for SL-172154 and SL-279252, development of GADLEN™ platform.
- Financial Condition: Strong financial backing with potential milestone payments from partnerships.
- Partnerships: Collaborations with Ono Pharmaceutical and Takeda Pharmaceuticals.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, will participate in the BTIG Biotechnology Conference on August 10, 2021. The event will feature a fireside chat with CEO Taylor Schreiber, CMO Lini Pandite, and CFO Andrew Neill at 1:30 p.m. EST. Shattuck focuses on developing bi-functional fusion proteins targeting cancer and autoimmune diseases, with its lead program, SL-172154, currently in a Phase 1 trial. Another compound, SL-279252, is in Phase 1 trials in collaboration with Takeda Pharmaceuticals.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company, is set to provide a corporate and financial update for Q2 2021 on August 11, 2021, at 4:30 p.m. ET. The earnings call can be accessed via phone and will be available in archived format for up to 90 days afterward. Shattuck focuses on bi-functional fusion proteins to treat cancer and autoimmune diseases, with lead programs SL-172154 and SL-279252 currently in Phase 1 trials. The company leverages its proprietary ARC® platform for innovative therapies.
Shattuck Labs (NASDAQ: STTK) announced the appointment of Abhinav A. Shukla, Ph.D., as Chief Technical Officer. His extensive experience in biologics manufacturing and gene therapy is expected to enhance the company's capabilities in developing its ARC and GADLEN platform compounds. Dr. Shukla previously held senior positions at Redpin Therapeutics and CRISPR Therapeutics, contributing to numerous investigational new drug applications and commercialized therapeutics. Shattuck aims to advance its bi-functional fusion proteins targeting cancer and autoimmune diseases through its innovative platforms.
Shattuck Labs (NASDAQ: STTK) reported Q1 2021 financial results, showing a net loss of $11.8 million, or $0.28 per share, compared to a $6.6 million loss in Q1 2020. Cash and equivalents totaled $321.2 million as of March 31. The company is on track for initial dose-escalation data from its clinical trials of CD47 inhibitor SL-172154 and PD-1 inhibitor SL-279252 in the second half of 2021. R&D expenses rose to $10.3 million, reflecting ongoing clinical developments. Financial guidance indicates sufficient funds to support operations through 2024.
Shattuck Labs (NASDAQ: STTK), a biotechnology firm, announced participation in two upcoming conferences. CEO Taylor Schreiber will discuss multifunctional soluble biologics at the 32nd Annual Cello Health Cancer Progress Conference on May 5, 2021, and ranking product attributes at the 17th Annual PEGS Boston Conference on May 11, 2021. The company focuses on developing bi-functional fusion proteins targeting cancer and autoimmune diseases, led by the SL-172154 program in Phase 1 trials, designed to block immune checkpoints.
Shattuck Labs, Inc. (NASDAQ: STTK) will participate in the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021. CEO Taylor Schreiber and CFO Andrew Neill will engage in a fireside chat at 1:50 p.m. EST. The event will be accessible via a live webcast, with a replay available for 90 days after the presentation. Shattuck specializes in developing bi-functional fusion proteins aimed at treating cancer and autoimmune diseases, leveraging their proprietary ARC® platform.
Shattuck Labs (NASDAQ: STTK) presented two posters at the AACR Annual Meeting on promising therapeutic developments. The first poster showcased SL-9258, a TIGIT-Fc-LIGHT fusion protein, demonstrating effectiveness against PD1 resistance in tumor models. The second presentation detailed GADLEN™, a platform targeting gamma delta T cells to treat hematologic malignancies. CEO Taylor Schreiber emphasized the innovation and potential to address unmet medical needs in cancer treatment. These advancements highlight Shattuck's commitment to pioneering new biologic medicines for cancer and autoimmune diseases.
Shattuck Labs, Inc. (NASDAQ: STTK) will participate in the 20th Annual Needham Healthcare Conference held virtually from April 12-15, 2021. CEO Taylor Schreiber, M.D., Ph.D., and CFO Andrew Neill will present on April 14, 2021, at 11:00 a.m. EST in a fireside chat format. The event can be accessed through a live webcast, with a replay available for up to 90 days. Shattuck Labs focuses on developing bi-functional fusion proteins aimed at treating cancer and autoimmune diseases, with its lead candidate SL-172154 currently in a Phase 1 trial.
Shattuck Labs (NASDAQ: STTK) announced the promotion of Andrew R. Neill to Chief Financial Officer, previously Vice President of Finance and Corporate Strategy. Neill is credited for his role in raising $330.5 million through recent financing efforts, which include Series B and B-1 financings and an IPO. CEO Taylor Schreiber emphasized Neill’s past contributions and strategic impact on advancing Shattuck's clinical-stage ARC compounds and GADLEN platform. Neill expressed enthusiasm for driving the company's growth in his new role, focusing on improving cancer treatment options.
Shattuck Labs (NASDAQ: STTK) reported its Q4 and full-year 2020 financial results, revealing a cash position of $335.4 million as of December 31, compared to $39.1 million in 2019. R&D expenses rose to $9.8 million for Q4 2020, while G&A expenses increased to $3.6 million. The net loss for Q4 was $12.0 million, or $0.31 per share, versus $7.4 million, or $0.97 per share in the prior year. Shattuck anticipates Phase 1 trial data for its lead CD47 checkpoint inhibitor SL-172154 and PD-1 inhibitor SL-279252 in H2 2021, while projecting sufficient cash to fund operations through 2024.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
What is Shattuck Labs, Inc.'s core business?
What are the main product candidates of Shattuck Labs?
What is the ARC® platform?
Who are Shattuck Labs' key partners?
Where is Shattuck Labs headquartered?
What is SL-172154?
What recent achievements has Shattuck Labs made?
What is the GADLEN™ platform?
What financial condition is Shattuck Labs in?
What are some upcoming events for Shattuck Labs?
